Dividendos de argenx

Dividendo controles de criterios 0/6

argenx no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$4.97
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

Jun 07

Argenx raises ~$1B in global offering

Feb 03

argenx to raise $750M in proposed global offering

Feb 01

argenx on target to file efgartigimod applications in Japan and Europe

Jan 08

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Jan 06

Argenx inks $98M deal to secure accelared review status for efgartigimod

Nov 23

argenx (ARGX) Investor Presentation - Slideshow

Nov 18

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ARGX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ARGX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de argenx vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ARGX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ARGX)	n/a
Suelo de mercado 25% (US)	1.6%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (ARGX)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ARGX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ARGX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de ARGX para determinar si sus dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ARGX no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de argenx

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx: A Very Good Start For Vyvgart

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

argenx: R&D Day Goes Unnoticed

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in the Lancet Neurology

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

argenx SE Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

argenx Issues Statement Concerning Efgartigimod

Argenx raises ~$1B in global offering

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

argenx to raise $750M in proposed global offering

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx on target to file efgartigimod applications in Japan and Europe

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

argenx and Zai Lab collaborate for Efgartigimod in Greater China

Argenx inks $98M deal to secure accelared review status for efgartigimod

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx (ARGX) Investor Presentation - Slideshow

argenx Announces Partnership with Chugai and the Clayton Foundation

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies